Leerink Swann reissued their outperform rating on shares of bluebird bio, Inc. (NASDAQ:BLUE) in a research report report published on Wednesday, November 1st, The Fly reports. The brokerage currently has a $162.00 target price on the biotechnology company’s stock, up from their prior target price of $145.00.
Several other equities analysts also recently weighed in on the company. Cantor Fitzgerald reissued a sell rating and set a $39.00 price target on shares of bluebird bio in a research report on Thursday, September 28th. BMO Capital Markets raised their price target on bluebird bio from $134.00 to $162.00 and gave the stock a buy rating in a research report on Monday, October 30th. Morgan Stanley downgraded bluebird bio from an equal weight rating to an underweight rating and set a $105.00 price target for the company. in a research report on Monday, October 2nd. Evercore ISI raised bluebird bio from an in-line rating to an outperform rating and set a $102.00 price target for the company in a research report on Monday, October 16th. Finally, Jefferies Group LLC reissued a hold rating and set a $126.00 price target on shares of bluebird bio in a research report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $131.05.
Shares of bluebird bio (BLUE) opened at $165.40 on Wednesday. bluebird bio has a 1-year low of $56.80 and a 1-year high of $165.52.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The firm had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. During the same period in the previous year, the business earned ($2.07) earnings per share. The business’s revenue for the quarter was up 397.4% on a year-over-year basis. research analysts expect that bluebird bio will post -6.68 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was published by BBNS and is the sole property of of BBNS. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://baseballnewssource.com/markets/bluebird-bio-inc-blue-rating-reiterated-by-leerink-swann/1749313.html.
In other bluebird bio news, insider Jeffrey T. Walsh sold 1,250 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $107.06, for a total value of $133,825.00. Following the completion of the sale, the insider now directly owns 28,555 shares in the company, valued at $3,057,098.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jeffrey T. Walsh sold 35,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $151.38, for a total value of $5,298,300.00. Following the completion of the sale, the insider now owns 62,305 shares of the company’s stock, valued at $9,431,730.90. The disclosure for this sale can be found here. Insiders have sold 193,168 shares of company stock valued at $25,558,003 over the last ninety days. Corporate insiders own 3.90% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ladenburg Thalmann Financial Services Inc. increased its holdings in shares of bluebird bio by 454.2% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 813 shares in the last quarter. QS Investors LLC increased its holdings in shares of bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 500 shares in the last quarter. Biondo Investment Advisors LLC bought a new position in shares of bluebird bio in the third quarter valued at $203,000. World Asset Management Inc bought a new position in shares of bluebird bio in the third quarter valued at $230,000. Finally, Bank of Montreal Can increased its holdings in shares of bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 911 shares in the last quarter.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with our FREE daily email newsletter.